Viking Therapeutics stock: VK2735 programs advance after Q3 update

Published on 11/01/2026 at 13:26 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Viking Therapeutics outlined progress in its obesity pipeline after its third-quarter update. Oral and injectable VK2735 programs remain central to its next clinical steps.

VK2735 programs move forward

Viking Therapeutics reported its third-quarter 2026 results and provided a corporate update on October 28.
The company said its VANQUISH Phase 3 trials for injectable VK2735 are advancing.
Viking has initiated the SUNRISE Phase 3 program for oral VK2735 in obesity.

VKTX, US92686J1060, Illustration mit AI erstellt.

Viking Therapeutics reported its third-quarter 2026 results and provided a corporate update on October 28, according to the company's investor-relations page. The update keeps the clinical development of VK2735 at the center of the company's outlook.

Obesity pipeline remains the focus

Viking said its VANQUISH Phase 3 trials for subcutaneous VK2735 continue to advance. The program is designed to evaluate the candidate in obesity, a market where clinical progress and later regulatory milestones will remain important drivers for the company.

The company also said it has initiated the SUNRISE Phase 3 trials for oral VK2735. The oral program expands Viking's development strategy beyond the injectable formulation and gives investors another set of clinical milestones to track.

Clinical milestones shape investor view

Viking's corporate profile describes VK2735 as a dual agonist of the GLP-1 and GIP receptors. The company is also developing VK2809 for lipid and metabolic disorders and VK0214 for X-linked adrenoleukodystrophy, but the current update highlights the advancing VK2735 obesity programs.

The real-time quote of Viking Therapeutics stock showed the shares at 24.45 euros on Lang & Schwarz at 13:04 CET on Saturday, October 31, 2026.

For the broader US market, investors can follow the S&P 500 alongside company-specific biotechnology developments.

More updates are available in more news and analyses on Viking Therapeutics stock.